11
Osamu Asano, Hitoshi Harada, Yorihisa Hoshino, Seiji Yoshikawa, Takashi Inoue, Tatsuo Horizoe, Nobuyuki Yasuda, Kaya Nagata, Junsaku Nagaoka, Manabu Murakami, Seiichi Kobayashi: Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes. Eisai, Birch Stewart Kolasch & Birch, June 17, 2003: US06579868 (65 worldwide citation)

The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action.


12
Graczyk Piotr, Khan Afzal, Bhatia Gurpreet, Iimura Yoichi: Jnk inhibitors. Eisai, Graczyk Piotr, Khan Afzal, Bhatia Gurpreet, Iimura Yoichi, CORNISH Kristina Victoria Joy, September 16, 2004: WO/2004/078756 (65 worldwide citation)

The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptos ...


13
Asano Osamu, Harada Hitoshi, Hoshino Yorihisa, Yoshikawa Seiji, Inoue Takashi, Horizoe Tatsuo, Yasuda Nobuyuki, Nagata Kaya, Nagaoka Junsaku, Murakami Manabu, Kobayashi Seiichi: Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes. Eisai, November 22, 2000: EP1054012-A1 (63 worldwide citation)

The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof ha ...


14
Takahashi Tohru, Sugimoto Hachiro: Quinazoline compounds. Eisai, Woodhams Blanchard and Flynn, November 18, 1975: US3920636 (60 worldwide citation)

2-(4'-SUBSTITUTED HOMOPIPERAZINO)-4-AMINO-6,7-DIMETHOXY-QUINAZOLINES HAVING THE FOLLOWING CHEMICAL FORMULA (I): v,2/14Wherein A represents a group selected from the following (i) and (ii):(i) R.sup.1 --CO--:wherein R.sup.1 represents a lower alkyl group of C.sub.1 -C.sub.4 ; phenyl group substituted ...


15
Ueno Kohshi, Sasaki Atsushi, Kawano Koki, Okabe Tadashi, Kitazawa Noritaka, Takahashi Keiko, Yamamoto Noboru, Suzuki Yuichi, Matsunaga Manabu, Kubota Atsuhiko: Fused pyridine derivatives. Eisai, July 19, 2000: EP1020445-A1 (60 worldwide citation)

Clinically highly useful drugs having an antagonism to serotonin, in particular, central muscle relaxing drugs for treating, ameliorating or preventing spastic paralysis or ameliorating myotonia and comprising fused pyridine derivatives represented by general formula (I), pharmacologically acceptabl ...


16
Yoshikawa Seiji, Emori Eita, Matsuura Fumiyoshi, Richard Clark, Ikuta Hironori, Kira Kazunobu, Yasuda Nobuyuki, Nagakura Tadashi, Yamazaki Kazuto: Novel fused imidazole derivative. Eisai, March 16, 2005: EP1514552-A1 (57 worldwide citation)

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substi ...


17
Jonathan K Leland, Haresh P Shah, John H Kenten, Jack E Goodman, George E Lowke, Yuzaburo Namba, Gary F Blackburn, Richard J Massey: Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets. Igen International, Eisai, Barry Evans Esq, David Rubin Esq, Curtis Morris & Safford P C, January 6, 1998: US05705402 (56 worldwide citation)

Disclosed and claimed are methods and apparatus for performing a binding assay for an analyte of interest present in a sample based upon measurement of electrochemiluminescence at an electrode. The method uses magnetically responsive particles. The method and apparatus call for a plurality of electr ...


18
Yasuda Nobuyuki, Yamazaki Kazuto: (Ja) 併用医薬, (En) Combination drug. Eisai, Yasuda Nobuyuki, Yamazaki Kazuto, SHIMIZU Hatsushi, April 8, 2004: WO/2004/028524 (56 worldwide citation)

(EN) It is intended to provide a drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide characterized by potentiating the effect of activated glucagon-like peptide-1 (GLP-1) in blood and/or activated glucagon-like peptide-2 (GLP-2) in blood.(JA) 本発明は、血中活性型グルカゴン様ペ ...


19
Norihito Ohi, Nobuaki Sato, Motohiro Soejima, Takashi Doko, Taro Terauchi, Yoshimitsu Naoe, Takafumi Motoki: Pyrazole compound and medicinal composition containing the same. Eisai R & D Management, Birch Stewart Kolasch & Birch, September 30, 2008: US07429609 (55 worldwide citation)

The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates —(CO)h—(NRa)j—(CRb═CRc)k—Ar (wherein Ra, Rb and Rc each independently designate ...


20
Hachiro Sugimoto, Yutaka Tsuchiya, Kunizou Higurashi, Norio Karibe, Youichi Iimura, Atsushi Sasaki, Yoshiharu Yamanishi, Hiroo Ogura, Shin Araki, Takashi Kosasa, Atsuhiko Kubota, Michiko Kosasa, Kiyomi Yamatsu: Cyclic amine compounds and pharmaceutical use. Eisai, Flynn Thiel Boutell & Tanis, March 31, 1992: US05100901 (53 worldwide citation)

A cyclic amine compound is defined by the formula: ##STR1## in which J is indanyl, indanonyl, indenyl, indenonyl, indanedionyl, tetralonyl, benzosuberonyl, indanolyl or a divalent group thereof, K is phenyl, an arylalkyl or cynnamyl, B is --(CHR22) r--, R22 being H or methyl, --CO-- (CHR22)r--, .dbd ...